By TAP Integrative
Hypertension affects approximately one third of all American adults, contributing to more than 360,000 deaths each year, according to the Centers for Disease Control and Prevention. Only half of those with hypertension have the condition under control. That is problematic as hypertension increases risk for heart attack, stroke, chronic heart failure, and kidney disease. Its increasing prevalence is a significant public health concern.
Nutritional approaches to hypertension are an important component of prevention and treatment. One area of research focus has been on the mineral magnesium, which is an essential element in the human body. Some studies have found that dietary magnesium intake may play a critical role in blood pressure management, but other studies have not been conclusive.
In an effort to reliably determine the effects of magnesium on hypertension, a team of researchers searched through the published literature and selected randomized, double-blind, and placebo controlled trials to analyze. The resulting meta-analysis, which included 34 trials and 2,028 participants, was published in 2016 in the journal Hypertension.
Using the data from these studies, the researchers determined that magnesium supplementation at a median dose of 368 mg per day and a median duration of three months significantly reduced blood pressure (systolic by 2.00 mm Hg, diastolic by 1.78 mm Hg). In addition, they found that a dose of 300 mg per day for one month is sufficient to reduce blood pressure. The studies that were most likely to find a positive effect were those that were well-designed or had the lowest dropout rates.
These findings suggest that magnesium supplementation has a causal effect in lowering blood pressure. Considering the rise in prevalence of hypertension and the serious risks associated with it, safe and effective measures such as magnesium supplementation have the potential to have a significant impact on public health.
Zhang X, Li Y, Del Gobbo LC, et al. Effects of magnesium supplementation on blood pressure: a meta-analysis of randomized double-blind placebo-controlled trials. Hypertension. 2016;68(2):324-333.
This content has been provided exclusively to Natural Partners by TAP Integrative. To learn more about TAP as well as details on how you can attain a discounted TAP Integrative membership, click here.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease